ImmunityBio Reports Strong Q1 Revenue Growth Despite EPS Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: seekingalpha
- Earnings Highlights: ImmunityBio reported a Q1 GAAP EPS of -$0.62, missing expectations by $0.55, indicating ongoing challenges in profitability despite strong revenue growth.
- Revenue Surge: The company achieved Q1 revenue of $44.2 million, representing an approximately 168% year-over-year increase, exceeding market expectations by $0.26 million, showcasing robust sales momentum.
- Quarter-over-Quarter Analysis: Compared to Q4 2025, ImmunityBio's revenue grew by 15%, demonstrating the company's competitive position and sustained demand for its products in the market.
- Market Reaction: Despite the strong revenue performance, ImmunityBio's shares fell by 7% following the earnings report, reflecting investor concerns over profitability that may impact future investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.890
Low
5.00
Averages
7.33
High
9.00
Current: 7.890
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Receives FDA Review for ANKTIVA Application
- FDA Review Progress: On May 19, ImmunityBio announced that the FDA accepted its supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat BCG-unresponsive non-muscle invasive bladder cancer, with a target decision date of January 6, 2027, which could significantly expand the drug's label and enhance its market competitiveness.
- Significant Sales Growth: The company confirmed ANKTIVA sales at $44.2 million, reflecting a 15% quarter-over-quarter increase and a remarkable 168% year-over-year growth, indicating strong market demand and solidifying its position in the immunotherapy sector.
- Analyst Rating Update: Following the earnings release, BTIG lowered its price target for ImmunityBio from $13 to $12 while maintaining a Buy rating, demonstrating market confidence in the company's growth potential despite some downside risks.
- Investment Outlook Analysis: While IBRX is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower risk, urging investors to carefully evaluate various investment opportunities to achieve optimal returns.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, misleading shareholders about the company's operations.
- ImmunityBio Allegations: ImmunityBio, Inc. (NASDAQ:IBRX) is implicated in a class action for the period from January 19, 2026, to March 24, 2026, where executives allegedly overstated Anktiva's capabilities, leading to materially misleading statements about the company's prospects and significant investor losses.
- Pinterest Revenue Concerns: Pinterest, Inc. (NYSE:PINS) is involved in a class action for the period from February 7, 2025, to February 12, 2026, with claims that the company failed to disclose risks of declining advertising revenues, potentially facing imminent restructuring, which has severely impacted investors.
- Legal Consultation Recommendation: Investors suffering losses in the aforementioned companies are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights and ensure their interests are protected in the class actions.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, citing misleading claims about Anktiva, which led to a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Initiation: Hagens Berman has initiated a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws and urging affected investors to submit their losses to support the investigation.
- Promotional Material Issues: The FDA highlighted that ImmunityBio's TV ads and podcast content were misleading, claiming Anktiva could cure all cancers without supporting data, which poses a potential public health risk and exacerbates legal vulnerabilities for the company.
- Investor Rights Protection: Hagens Berman emphasized its investigation into whether ImmunityBio intentionally misled investors and encouraged whistleblowers to provide information to assist the inquiry, demonstrating a commitment to protecting investor rights.
See More
Reminder for ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action, as those who do not will not be represented.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to seek compensation.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading efficacy claims made by its Chief Scientific Officer regarding its lead biologic product, Anktiva, during a podcast, with the class period spanning from January 19 to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials for Anktiva in a podcast and TV ad were false or misleading, resulting in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging affected investors to submit their losses while also encouraging witnesses to assist in the ongoing investigation, highlighting the firm's commitment to protecting shareholder rights.
- Public Health Impact: The FDA emphasized that ImmunityBio's promotional claims misrepresented Anktiva's benefits and failed to provide complete information regarding its FDA-approved indications, raising serious public health concerns about misleading patients regarding treatment expectations.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to contact them before May 26, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to safeguarding investor interests.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, underscoring the importance of participating in the lawsuit to ensure their rights are protected.
See More
ImmunityBio Receives FDA Review for ANKTIVA Application
- FDA Review Progress: On May 19, ImmunityBio announced that the FDA accepted its supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat BCG-unresponsive non-muscle invasive bladder cancer, with a target decision date of January 6, 2027, which could significantly expand the drug's label and enhance its market competitiveness.
- Significant Sales Growth: The company confirmed ANKTIVA sales at $44.2 million, reflecting a 15% quarter-over-quarter increase and a remarkable 168% year-over-year growth, indicating strong market demand and solidifying its position in the immunotherapy sector.
- Analyst Rating Update: Following the earnings release, BTIG lowered its price target for ImmunityBio from $13 to $12 while maintaining a Buy rating, demonstrating market confidence in the company's growth potential despite some downside risks.
- Investment Outlook Analysis: While IBRX is viewed as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower risk, urging investors to carefully evaluate various investment opportunities to achieve optimal returns.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Lawsuit: Super Micro Computer, Inc. (NASDAQ:SMCI) faces a class action for the period from April 30, 2024, to March 19, 2026, with investors claiming losses over $50,000 due to undisclosed sales to Chinese companies violating U.S. export laws, misleading shareholders about the company's operations.
- ImmunityBio Allegations: ImmunityBio, Inc. (NASDAQ:IBRX) is implicated in a class action for the period from January 19, 2026, to March 24, 2026, where executives allegedly overstated Anktiva's capabilities, leading to materially misleading statements about the company's prospects and significant investor losses.
- Pinterest Revenue Concerns: Pinterest, Inc. (NYSE:PINS) is involved in a class action for the period from February 7, 2025, to February 12, 2026, with claims that the company failed to disclose risks of declining advertising revenues, potentially facing imminent restructuring, which has severely impacted investors.
- Legal Consultation Recommendation: Investors suffering losses in the aforementioned companies are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights and ensure their interests are protected in the class actions.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, citing misleading claims about Anktiva, which led to a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Initiation: Hagens Berman has initiated a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws and urging affected investors to submit their losses to support the investigation.
- Promotional Material Issues: The FDA highlighted that ImmunityBio's TV ads and podcast content were misleading, claiming Anktiva could cure all cancers without supporting data, which poses a potential public health risk and exacerbates legal vulnerabilities for the company.
- Investor Rights Protection: Hagens Berman emphasized its investigation into whether ImmunityBio intentionally misled investors and encouraged whistleblowers to provide information to assist the inquiry, demonstrating a commitment to protecting investor rights.
See More
Reminder for ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action, as those who do not will not be represented.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to seek compensation.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading efficacy claims made by its Chief Scientific Officer regarding its lead biologic product, Anktiva, during a podcast, with the class period spanning from January 19 to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials for Anktiva in a podcast and TV ad were false or misleading, resulting in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging affected investors to submit their losses while also encouraging witnesses to assist in the ongoing investigation, highlighting the firm's commitment to protecting shareholder rights.
- Public Health Impact: The FDA emphasized that ImmunityBio's promotional claims misrepresented Anktiva's benefits and failed to provide complete information regarding its FDA-approved indications, raising serious public health concerns about misleading patients regarding treatment expectations.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to contact them before May 26, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to safeguarding investor interests.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, underscoring the importance of participating in the lawsuit to ensure their rights are protected.
See More
